AngioDynamics reports durable 2-year NanoKnife outcomes in PRESERVE prostate cancer trial

AngioDynamics

AngioDynamics

ANGO

0.00
  • AngioDynamics reported two-year results from PRESERVE, a pivotal U.S. study of its NanoKnife irreversible electroporation system in intermediate-risk prostate cancer; data will be presented May 17 at 2026 American Urological Association Annual Meeting.
  • Follow-up showed outcomes held up over time, with no additional signs of disease progression requiring further treatment in patients with available two-year assessments.
  • Safety profile remained stable, with no new device- or procedure-related issues emerging between year one and year two.
  • Update extends evidence beyond 12-month results published in European Urology in July 2025, supporting broader clinical adoption and reimbursement efforts for NanoKnife focal therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512803922) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.